Replies to post #88446 on Avid Bioservices Inc (CDMO)

[AspenMTB]

I agree and found the JMP & Wedbush decks very useful – especially when countering the argument that there is a problem with the control arm – IMO the author’s use of “recent phase 3 studies utilizing docetaxal” is less relevant than using the Docetaxel, ALIMTA and Tarceva package inserts footnoted - Wedbush slide no. 15.

Question for the experts (freethemice?) when do you think the second-line NSCLC P-values and HR will be revealed? Is proving statistical significance required prior to partnering/Phase III design?